News

Press Releases

 
Press Releases
  Date Title and Summary View
May 8, 2017
Ms. Johnson Received Athena Pinnacle Award and Will Receive MOXIE Award WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), and Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women's reproductive h...
Mar 20, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with Daré Bioscience that the companies will hold a joint conference call to discuss the definitive share purchase agreement under which the stockholders of Daré Bioscience will become the majority o...
Mar 20, 2017
Transaction to create NASDAQ-listed company focused on the development and commercialization of women's reproductive health products Sabrina Martucci Johnson to be Named CEO of Combined Company Cerulean and Daré to Host Joint Conference Call in March to Discuss Proposed Transa...
Feb 1, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Cerulean has engaged in...
Nov 3, 2016
Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities for the quarter ended September 30, 2016. ...
Oct 27, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the third quarter 2016 on November 3. Management will conduct a conference...
Oct 26, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Scott Eliasof, PhD, has been promoted to the role of Senior Vice President and Chief Scientific Officer, effective immediately. Dr. Eliasof j...
Oct 19, 2016
- Collaboration will create nanoparticle-drug conjugates directed at up to five targets - Cerulean will receive an upfront payment of $5 million and is eligible for milestone payments plus sales royalties for each target WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean ...
Oct 19, 2016
Initial purchase of 800,000 shares of common stock for $1.25 per share WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that it has entered into a $20 million common stock p...
Oct 6, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will present clinical data from its CRLX101 and CRLX301 programs at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting being ...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools